Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease - Scorecard - MDSpire

Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

  • By

  • Asmaa Mohamed Fteah

  • Doaa Mamdouh Aly

  • Mohamed A. Elrefaiy

  • Ali Abdel Rahim

  • April 13, 2026

  • 0 min

Share

Clinical Scorecard: Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationAdults with confirmed MASLD or clinically suspected MASH, with clear definitions provided.
Care Setting

Key Highlights

  • highlights

Guideline-Based Recommendations

Diagnosis

  • Use abdominal ultrasonography for hepatic steatosis detection, referencing AASLD guidelines.
  • Employ Controlled Attenuation Parameter (CAP) measurements for steatosis grading, citing specific cut-off values.

Management

  • Focus on lifestyle modifications and metabolic risk factor management, with evidence from recent studies.

Monitoring & Follow-up

    Risks

      Patient & Prescribing Data

      Detail how genetic predisposition may influence treatment response and disease progression.

      Clinical Best Practices

      • Integrate genetic testing for GCKR and FGF21 in risk assessment, supported by recent findings.
      • Utilize non-invasive biomarkers for monitoring disease activity, with references to studies validating their use.
      • Adopt a multidisciplinary approach for managing metabolic dysfunction, citing successful case studies.

      References

      Original Source(s)

      Genetic Variants in GCKR and Circulating FGF21 as Indicators of Metabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

      • by Asmaa Mohamed Fteah, Doaa Mamdouh Aly, Mohamed A. Elrefaiy, Ali Abdel Rahim

      • April 13, 2026

      Related Content

      Metabolomic signatures mediate the association between physical frailty and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

      Case Report: Hemophagocytic lymphohistiocytosis masquerading as drug-induced liver injury: successful treatment with low-dose ruxolitinib and glucocorticoids

      Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026